Change in the number of shares and votes in BioInvent International AB
BioInvent International AB announces an increase in its total shares to 58,471,096 as of March 31, 2021, following a directed issue that raised MSEK 819. This issuance involved 16,260,601 shares sold to institutional investors, approved by the General Meeting on March 23, 2021. BioInvent focuses on developing first-in-class immuno-modulatory antibodies for cancer therapy, with three candidates in clinical trials. Revenue is generated through research collaborations and license agreements with top pharmaceutical firms.
- Successfully raised MSEK 819 through share issuance, increasing total shares to 58,471,096.
- Three drug candidates in ongoing Phase I/II trials, demonstrating clinical development progress.
- None.
LUND, Sweden, March 31, 2021 /PRNewswire/ -- BioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the company's total number of shares as per March 31, 2021 amounts to 58,471,096 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the directed issue of MSEK 819 to international and Swedish institutional investors by issuance of 16,260,601 shares, announced on February 23, 2021 and approved by the General Meeting on March 23, 2021.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
This information is information that BioInvent International AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 08:30 a.m. CEST on March 31, 2021.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Change in the number of shares and votes in BioInvent International AB |
View original content:http://www.prnewswire.com/news-releases/change-in-the-number-of-shares-and-votes-in-bioinvent-international-ab-301259271.html
SOURCE BioInvent International AB
FAQ
What is the total number of shares for BioInvent as of March 31, 2021?
How much capital did BioInvent raise through its directed share issue?
When was the directed share issue approved by the General Meeting?
What type of therapies does BioInvent develop?
How many drug candidates does BioInvent have in clinical trials?
